Abstract
Four of 10 patients who were enrolled on protocols of high-dose immunosuppression with peripheral blood stem cell rescue for MS experienced neurologic worsening while receiving recombinant human granulocyte colony-stimulating factor. There was improvement when methylprednisolone was given to three of the patients, but one patient died of respiratory failure. The mechanism of the neurologic worsening is uncertain.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Anti-Inflammatory Agents / therapeutic use
-
Female
-
Granulocyte Colony-Stimulating Factor / adverse effects*
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Humans
-
Male
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Multiple Sclerosis / drug therapy*
-
Paralysis / chemically induced
-
Paralysis / drug therapy
-
Recombinant Proteins
Substances
-
Anti-Inflammatory Agents
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Methylprednisolone